Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 12098141
Bicyclic indazole glucocorticoid receptor antagonists
granted -
US 12097213
Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy
granted -
US 12097199
Administration of SUMO-activating enzyme inhibitor and anti-CD20 antibodies
granted -
US 12097188
Compositions and methods for the treatment of macular degeneration
granted -
US 12097185
Compositions comprising ciprofloxacin and celecoxib
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12098152
Methods and compositions for treating polycystic ovary syndrome
granted -
US 12097291
Thermostable vaccine compositions and methods of preparing same
granted -
US 12097219
Single-domain antibodies against CLL1 and constructs thereof
granted -
US 12097210
Concomitant administration of glucocorticoid receptor modulators and CYP3A inhibitors
granted -
US 12097198
Treatment of prostate cancer
granted -
WO 2024194388
PREPARATION DE LEVURE SACCHAROMYCES BOULARDII INACTIVEE
granted -
US 12102671
Method of vaccination with an attenuated RSV vaccine formulation
granted -
US 12103958
Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions
granted -
US 12103926
Compounds for treating huntington's disease
granted -
US 12103960
VEGF traps and mini-traps and methods for treating ocular disorders and cancer
granted -
US 12104165
Adeno-associated virus with engineered capsid
granted -
US 12104172
Processes for generating TIL products enriched for tumor antigen-specific t-cells
granted -
US 12104185
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12102682
Injectable photothermal hydrogel based on melanin, preparation method, and application thereof
granted -
US 12102640
Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
granted -
US 12102619
Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
granted -
US 12102642
Treatment of hypercoagulopathy in Cushing's syndrome by administration of glucocorticoid receptor modulators
granted -
US 12102662
Methods for storing and warming purified corticotropin compositions
granted -
US 12102637
Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
granted -
US 12102609
Methods of administering solriamfetol to lactating women
granted -
US 12102668
Process, tube and device for the preparation of wound healant composition
granted -
US 12102646
Compositions for the treatment of fibrosis and inflammation
granted -
US 12102688
Immunomodulatory nanofilaments
granted -
US 12102617
Antimicrobial compositions containing a synergistic combination of activated creatinine and an imidazole antifungal agent
granted -
US 12103907
Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
granted -
US 12102687
Muscle targeting complexes and uses thereof for treating myotonic dystrophy
granted -
US 12104163
Adeno-associated virus vectors for treatment of Rett syndrome
granted -
US 12104184
PH20 polypeptide variants, formulations and uses thereof
granted -
US 12104188
Modified caspase-9 polypeptides and methods of use thereof
granted -
US 12102606
Dosage forms and methods for enantiomerically enriched or pure bupropion
granted -
US 12104181
Compositions and methods for treating viral infections targeting TRIM7
granted -
US 12103978
Methods and materials for treating cancer
granted -
US 12102694
Radiolabeled compound producing method and producing apparatus, radiolabeled compound and radioisotope producing apparatus
granted -
WO 2024206551
COMPOSITIONS ET PROCÉDÉS DE RÉHYDRATATION D'ALGUES MARINES
granted -
AU 2023244944
PRODRUGS OF OPICAPONE
granted -
US 2024327366
POLYMORPH FORM OF PITOLISANT HYDROCHLORIDE
granted -
WO 2024200854
ANTICORPS DE LIAISON AUX ALLERGÈNES APPROPRIÉS POUR TRAITER DES ALLERGIES AU POLLEN D'ARBRE
granted -
PT 3721882
TREATMENT OF METABOLIC DISORDERS IN EQUINE ANIMALS
granted -
IT 202300006237
COMPOSIZIONI NUTRACEUTICHE PER IL TRATTAMENTO O PREVENZIONE DI DISORDINI CONNESSI ALLA TRIMETILAMINURIA.
granted -
US 12110334
Neutralizing antibodies to the αvβ8 integrin complex for immunotherapy
granted -
US 12110315
Fish-derived peptidoglycan recognition protein mutant and application thereof
granted -
US 12110344
Antibodies that bind to cis and uses thereof
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.